サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：緑内障市場規模・シェア・動向分析レポート：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、セグメント予測、2023年～2030年
市場調査レポート
商品コード
1321347

緑内障市場規模・シェア・動向分析レポート：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、セグメント予測、2023年～2030年

Glaucoma Market Size, Share & Trends Analysis Report By Disease Type (Open Angle Glaucoma, Angle Closure Glaucoma), By Drug Class (Prostaglandins Analogs, Beta-blockers), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
緑内障市場規模・シェア・動向分析レポート：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、セグメント予測、2023年～2030年
出版日: 2023年07月06日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

緑内障市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の緑内障市場規模は2023年から2030年にかけてCAGR 4.61％で拡大し、2030年には115億2,000万米ドルに達すると予測されています。

緑内障の有病率の上昇、個別化治療戦略の取り込み、患者の意識の高まりが市場成長の原動力となっています。患者中心のケアは、疾患の治療においてますます重要になってきています。これには、自己管理、患者教育、共同意思決定などの技術が含まれます。患者を教育し、治療法の選択に参加させることで、患者の治療へのアドヒアランス、治療への満足度、全体的な治療成績はすべて向上します。

緑内障業界には強力なパイプラインがあり、将来の成長を促進すると予想されています。例えば、2023年4月のScience Advances Journalによると、科学者たちはこの病気を治療するための新しい遺伝子治療を開発しています。Exhaura LtdとSmurfit Institute of Geneticsの共同研究がこの製品を開発しています。新規治療法の開発をサポートする研究開発チームの存在は、市場の成長を促進すると予測されています。例えば、2023年3月、IU医科大学は、眼科学部門が緑内障治療を支援するために人工多能性幹細胞を使用することに取り組んでいると発表しました。

さらに、人口の間で失明の発生率が増加しているため、より多くの人々が早期治療を選択し、業界の成長を推進しています。例えば、2020年に世界保健機関（WHO）が発表した報告によると、緑内障は白内障に次いで失明の2番目の主な原因となっています。インドでは1,190万人の緑内障による失明が報告されています。視力喪失の負担増が治療薬や生物製剤の需要増につながり、業界の成長を後押ししています。

糖尿病や加齢黄斑変性（AMD）、白内障、ドライアイなどの眼疾患を持つ患者は、緑内障を発症しやすいです。このように、眼疾患に罹患しやすい高齢者人口の増加が、緑内障治療薬の需要を促進しています。さらに、主要企業は、この疾患の治療に使用される新製品を発売し、製品ポートフォリオの拡充に取り組んでいます。例えば、Teva Pharmaceuticals USA, Inc.は2021年3月、米国で1% AZOPT（ブリンゾラミド点眼液）の初のジェネリック医薬品の発売を発表しました。この製品は、開放隅角緑内障や高眼圧症による眼圧上昇の治療に使用されます。

緑内障市場レポートハイライト

  • 疾患タイプ別では、治療用生物製剤の市場開発により、開放隅角緑内障分野が2022年の市場を独占しました。
  • 薬剤クラス別では、プロスタグランジンアナログが2022年に最大の市場シェアを占めました。
  • 流通チャネル別では、病院薬局部門が2022年に最大の市場シェアを占めました。病院薬局はアクセスしやすく、適格な指導が受けられるため、患者にとって有益です。
  • 北米は、2022年の市場シェア38.60%を占め、強い地域的地位を確立しています。これは、同地域の研究開発活動が、政府からの資金提供の増加や治療法の採用率の高さによって成長した結果です。
  • 主な参入企業には、ファイザー、参天製薬、ノバルティス、アルコン、アクロン・オペレーティング・カンパニー、テア・ファーマ、アッヴィ、ボシュロム、テバ・ファーマシューティカルズ・インダストリーズなどがあります。

目次

第1章 調査手法と範囲

  • 市場セグメンテーション
  • 目的
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • Gvrの内部データベース
    • 二次情報
    • 1次調査
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の形成と検証
  • モデル詳細
    • 商品フロー分析
  • 二次情報のリスト
  • 略語のリスト
  • 一次情報のリスト

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/アンシラリー市場の見通し
  • 市場力学
  • 市場促進要因
    • 業界の主要企業間でのコラボレーションとパートナーシップの強化
    • 斬新な製品の発売
    • 眼科分野の研究開発の増加
  • 市場抑制要因分析
    • この病気に対する認識の欠如と過少診断
    • 高額な治療費
  • 事業環境分析
    • SWOT分析：要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • COVID-19の影響分析

第4章 疾患別ビジネス分析

  • 緑内障市場：疾患タイプの変動分析
  • 開放隅角緑内障
    • 開放隅角緑内障市場、2018～2030年
  • 閉塞隅角緑内障
    • 閉塞隅角緑内障市場、2018年～2030年
  • その他

第5章 医薬品クラスのビジネス分析

  • 緑内障市場：薬剤クラスの変動分析
  • プロスタグランジン類アナログ市場、2018年～2030年
  • ベータブロッカー
  • アドレナリン作動薬
  • 炭酸脱水酵素阻害剤
  • その他

第6章 流通チャネルのビジネス分析

  • 緑内障市場：流通チャネルの変動分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域ビジネス分析

  • 地域別緑内障市場シェア、2022年および2030年
  • 北米
    • 北米緑内障市場、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州緑内障市場、2018～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋の緑内障市場、2018年から2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの緑内障市場、2018～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカの緑内障市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • 緑内障市場シェア分析、2022年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 3 Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Glaucoma Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 North America Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Canada Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 19 Europe Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Germany Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 UK Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 UK Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 France Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 28 France Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Italy Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Italy Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Spain Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Spain Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Denmark Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Denmark Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Sweden Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Sweden Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Norway Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Norway Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 China Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 China Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 50 China Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Japan Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 India Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 55 India Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 56 India Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 South Korea Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 South Korea Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Australia Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Australia Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Thailand Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 65 Thailand Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Latin America Glaucoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 69 Latin America Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Brazil Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 Brazil Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Mexico Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Mexico Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Argentina Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 85 South Africa Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 91 UAE Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Glaucoma Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Glaucoma Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Glaucoma Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Glaucoma Market: Disease Type Movement Analysis
  • Fig. 17 Global Glaucoma Market, by Open Angle Glaucoma, 2018 - 2030 (USD Million)
  • Fig. 18 Global Glaucoma Market, by Angle Closure Glaucoma, 2018 - 2030 (USD Million)
  • Fig. 19 Global Glaucoma Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 20 Global Glaucoma Market: Drug Class Movement Analysis
  • Fig. 21 Global Glaucoma Market, by Prostaglandins Analogs, 2018 - 2030 (USD Million)
  • Fig. 22 Global Glaucoma Market, by Beta-blockers, 2018 - 2030 (USD Million)
  • Fig. 23 Global Glaucoma Market, by Adrenergic Agonists, 2018 - 2030 (USD Million)
  • Fig. 24 Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 25 Global Glaucoma Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Glaucoma Market: Distribution Channel Movement Analysis
  • Fig. 27 Global Glaucoma Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
  • Fig. 28 Global Glaucoma Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 29 Global Glaucoma Market, by Online Pharmacy, 2018 - 2030 (USD Million)
  • Fig. 30 Regional Marketplace: Key Takeaways
  • Fig. 31 Regional Outlook, 2022 & 2030
  • Fig. 32 Global Glaucoma Market: Region Movement Analysis
  • Fig. 33 North America Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 46 Japan Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 47 China Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 48 India Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 49 Australia Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Glaucoma Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Glaucoma Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-095-0

Glaucoma Market Growth & Trends

The global glaucoma market size is expected to reach USD 11.52 billion by 2030, expanding at a CAGR of 4.61% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of glaucoma, incorporation of individualized treatment strategies and growing patient awareness are driving the market growth. Patient-centered care is becoming increasingly important for the treatment of the disease. This covers techniques for self-management, patient education, and collaborative decision-making. Patients' adherence to treatments, contentment with them, and overall outcomes can all be enhanced by educating them and including them in treatment choices.

The glaucoma industry has a strong pipeline, which is anticipated to fuel future growth. For instance, as per Science Advances Journal in April 2023, scientists are developing a novel gene therapy to treat the disease. The collaboration of Exhaura Ltd and Smurfit Institute of Genetics is developing this product. The presence of research and development teams supporting the development of novel treatments is projected to propel market growth. For instance, in March 2023, IU School of Medicine announced its Department of Opthalmology is working on using induced pluripotent stem cells to aid glaucoma treatment.

Moreover, the increasing incidence of blindness among the population is propelling the industry growth as the more aware population opts for early treatment. For instance, as per the reports published by World Health Organization in 2020, glaucoma was the second major cause of blindness after cataracts. India reported 11.9 million cases of glaucoma-associated blindness. The increasing burden of vision loss led to the increasing demand for therapeutics and biologics, which boosts the industry growth.

Patients with diabetes and other eye conditions, such as Age-related Macular Degeneration (AMD), cataract, and dry eye, are more prone to developing glaucoma. Thus, the growing elderly population, which is highly susceptible to eye diseases is propelling the demand for glaucoma drugs. Moreover, key players are involved in product portfolio expansion with the launch of novel products used to treat the disease. For instance, in March 2021, Teva Pharmaceuticals USA, Inc. announced the launch of the first generic version of 1% AZOPT (brinzolamide ophthalmic solution) in the U.S., which is used to treat high levels of pressure inside the eye caused due to open-angle glaucoma and ocular hypertension.

Glaucoma Market Report Highlights

  • By disease type, the open-angle glaucoma segment dominated the market in 2022 owing to the development of biologics for the treatment of the disease
  • By drug class, the prostaglandin analogs segment held the largest market share in 2022, attributable to their safety and universal acceptance as the first-line treatment option
  • By distribution channel, the hospital pharmacy segment held the largest market share in 2022. The patients benefit from the hospital pharmacy as it provides accessibility and qualified guidance
  • North America has established a strong regional position with a 38.60% market share in 2022. This is a result of the region's R&D activity growing due to increased government funding and a high adoption rate of treatments
  • A few of the key industry players include Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Novartis AG; Alcon Inc.; Akron Operating Company LLC; Thea Pharma; AbbVie, Inc.; Bausch & Lomb Incorporated; and Teva Pharmaceuticals Industries Ltd.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type And Drug Class Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing Collaboration And Partnerships Among The Industry's Key Players
    • 3.4.2. Novel Product Launch
    • 3.4.3. Increasing R&D In The Ophthalmology Sector
  • 3.5. Market Restraint Analysis
    • 3.5.1. Lack Of Awareness And Underdiagnoses Of The Disease
    • 3.5.2. High Cost Of The Treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

  • 4.1. Glaucoma Market: Disease Type Movement Analysis
  • 4.2. Open Angle Glaucoma
    • 4.2.1. Open Angle Glaucoma Market, 2018 - 2030 (USD Million)
  • 4.3. Angle Closure Glaucoma
    • 4.3.1. Angle Closure Glaucoma Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Drug Class Business Analysis

  • 5.1. Glaucoma Market: Drug Class Movement Analysis
  • 5.2. Prostaglandins Analogs Market, 2018 - 2030 (USD Million)
  • 5.3. Beta-Blockers
    • 5.3.1. Beta-Blockers Market, 2018 - 2030 (USD Million)
  • 5.4. Adrenergic Agonists
    • 5.4.1. Adrenergic Agonists Market, 2018 - 2030 (USD Million)
  • 5.5. Carbonic Anhydrase Inhibitors
    • 5.5.1. Carbonic Anhydrase Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Glaucoma Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacy
    • 6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Glaucoma Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.3. Uk
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. Uk Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Glaucoma Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Glaucoma Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Glaucoma Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's Overview
  • 8.2. Financial Performance
  • 8.3. Participant Categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Glaucoma Market Share Analysis, 2022
    • 8.3.3. Company Profiles
      • 8.3.3.1. Pfizer Inc.
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. Santen Pharmaceutical Co., Ltd.
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Novartis Ag
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Akron Operating Company Llc
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Thea Pharma
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbvie, Inc.
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Bausch + Lomb Corporation
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Teva Pharmaceuticals Industries Ltd.
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Alcon Inc.
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others